Successful treatment of dupilumab‐resistant scaly erythroderma in Netherton syndrome with baricitinib: A case report
The Journal of Dermatology · 2024-11 · 51 (11)
DOI: 10.1111/1346-8138.17335 ↗Kurz gefasst
Leserbrief in der Zeitschrift The Journal of Dermatology, online erschienen am 05.07.2024. Verfasst von Tomoya Takegami und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
- Skin Research Institute of Singapore (SRIS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
ORCID-Profile: Tomoya Takegami, Satoru Yonekura, Saeko Nakajima
Zitieren
APA
Takegami, T., Yonekura, S., Nakajima, S., & Kabashima, K. (2024). Successful treatment of dupilumab‐resistant scaly erythroderma in Netherton syndrome with baricitinib: A case report. The Journal of Dermatology, 51(11). https://doi.org/10.1111/1346-8138.17335
Vancouver
Takegami T, Yonekura S, Nakajima S, Kabashima K. Successful treatment of dupilumab‐resistant scaly erythroderma in Netherton syndrome with baricitinib: A case report. The Journal of Dermatology. 2024;51(11). doi:10.1111/1346-8138.17335
BibTeX
@article{Takegami2024,
author = {Takegami, Tomoya and Yonekura, Satoru and Nakajima, Saeko and Kabashima, Kenji},
title = {Successful treatment of dupilumab‐resistant scaly erythroderma in Netherton syndrome with baricitinib: A case report},
journal = {The Journal of Dermatology},
year = {2024},
volume = {51},
number = {11},
doi = {10.1111/1346-8138.17335}
}
EUVIMED